Cancer BiologybioRxivPreprint
CDK7 is a Novel Therapeutic Vulnerability in Fibrolamellar Carcinoma
M. Nukaya, C. Cafferty, K. Zahed…·S. M. Ronnekleiv-Kelly
This study identifies CDK7 as a therapeutic target in fibrolamellar carcinoma by showing its activation in FLC cells and efficacy of CDK7 inhibitors in patient-derived models.
DOI 10.1101/2023.04.22.537934